Vitamin D-dependent suppression of endothelin-induced vascular smooth muscle cell proliferation through inhibition of CDK2 activity

Journal of Steroid Biochemistry and Molecular Biology

Volumn 118, Issue 3, 2010, Pages 135-141

  Chen, Songcang ^a   Law, Christopher S ^a   Gardner, David G ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cell cycle; Cyclin dependent kinase 2; Vascular smooth muscle cells; Vitamin D

Indexed keywords

9,10 SECOCHOLESTA 5,7,10(19),16 TETRAEN 23 YNE 1,3,25 TRIOL; CALCITRIOL; CYCLIN DEPENDENT KINASE 2; ENDOTHELIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; RO 25 6760; UNCLASSIFIED DRUG; VITAMIN D DERIVATIVE;

ANIMAL CELL; AORTA; ARTICLE; CELL CULTURE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA SYNTHESIS; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; MITOGENESIS; NEWBORN; NONHUMAN; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; VASCULAR SMOOTH MUSCLE;

ANIMALS; ANIMALS, NEWBORN; CALCITRIOL; CELL PROLIFERATION; CELLS, CULTURED; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR PROTEINS; CYCLIN-DEPENDENT KINASES; CYCLINS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FLAVONOIDS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; PROTEIN KINASE INHIBITORS; RATS; RECEPTORS, CALCITRIOL; SIGNAL TRANSDUCTION; VITAMIN D;

RATTUS;

EID: 74449093547     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2009.11.002     Document Type: Article

References (38)

1. Holick M.F. Vitamin D deficiency. N. Engl. J. Med. 357 3 (2007) 266-281
2. Banwell C.M., Singh R., Stewart P.M., Uskokovic M.R., and Campbell M.J. Antiproliferative signalling by 1,25(OH)2D3 in prostate and breast cancer is suppressed by a mechanism involving histone deacetylation. Recent Results Cancer Res. 164 (2003) 83-98
3. Mehta R.G., and Mehta R.R. Vitamin D and cancer. J. Nutr. Biochem. 13 5 (2002) 252-264
4. Pendas-Franco N., Garcia J.M., Pena C., Valle N., Palmer H.G., Heinaniemi M., Carlberg C., Jimenez B., Bonilla F., Munoz A., and Gonzalez-Sancho J.M. DICKKOPF-4 is induced by TCF/beta-catenin and upregulated in human colon cancer, promotes tumour cell invasion and angiogenesis and is repressed by 1alpha,25-dihydroxyvitamin D(3). Oncogene 27 32 (2008) 4467-4477
5. Kawa S., Yoshizawa K., Nikaido T., and Kiyosawa K. Inhibitory effect of 22-oxa-1,25-dihydroxyvitamin D3, maxacalcitol, on the proliferation of pancreatic cancer cell lines. J. Steroid. Biochem. Mol. Biol. 97 1-2 (2005) 173-177
6. Schwartz G.G., Eads D., Naczki C., Northrup S., Chen T., and Koumenis C. 19-nor-1alpha,25-dihydroxyvitamin D2 (Paricalcitol) inhibits the proliferation of human pancreatic cancer cells in vitro and in vivo. Cancer Biol. Ther. 7 3 (2007)
7. Rao A., Coan A., Welsh J.E., Barclay W.W., Koumenis C., and Cramer S.D. Vitamin D receptor and p21/WAF1 are targets of genistein and 1,25-dihydroxyvitamin D3 in human prostate cancer cells. Cancer Res. 64 6 (2004) 2143-2147
8. Kajikawa M., Ishida H., Fujimoto S., Mukai E., Nishimura M., Fujita J., Tsuura Y., Okamoto Y., Norman A.W., and Seino Y. An insulinotropic effect of vitamin D analog with increasing intracellular Ca2+ concentration in pancreatic beta-cells through nongenomic signal transduction. Endocrinology 140 10 (1999) 4706-4712
9. Zeitz U., Weber K., Soegiarto D.W., Wolf E., Balling R., and Erben R.G. Impaired insulin secretory capacity in mice lacking a functional vitamin D receptor. FASEB J. 17 3 (2003) 509-511
10. van Etten E., and Mathieu C. Immunoregulation by 1,25-dihydroxyvitamin D3: basic concepts. J. Steroid Biochem. Mol. Biol. 97 1-2 (2005) 93-101
11. Beckerman P., and Silver J. Vitamin D and the parathyroid. Am. J. Med. Sci. 317 6 (1999) 363-369
12. Rodriguez M.E., Almaden Y., Canadillas S., Canalejo A., Siendones E., Lopez I., Aguilera-Tejero E., Martin D., and Rodriguez M. The calcimimetic R-568 increases vitamin D receptor expression in rat parathyroid glands. Am. J. Physiol. Renal Physiol. 292 5 (2007) F1390-1395
13. Nibbelink K.A., Tishkoff D.X., Hershey S.D., Rahman A., and Simpson R.U. 1,25(OH)2-vitamin D3 actions on cell proliferation, size, gene expression, and receptor localization, in the HL-1 cardiac myocyte. J. Steroid Biochem. Mol. Biol. 103 3-5 (2007) 533-537
14. Walters M.R., Wicker D.C., and Riggle P.C. 1,25-Dihydroxyvitamin D3 receptors identified in the rat heart. J. Mol. Cell Cardiol. 18 1 (1986) 67-72
15. Mitsuhashi T., Morris Jr. R.C., and Ives H.E. 1,25-Dihydroxyvitamin D3 modulates growth of vascular smooth muscle cells. J. Clin. Invest. 87 6 (1991) 1889-1895
16. Eelen G., Gysemans C., Verlinden L., Vanoirbeek E., De Clercq P., Van Haver D., Mathieu C., Bouillon R., and Verstuyf A. Mechanism and potential of the growth-inhibitory actions of vitamin D and analogs. Curr. Med. Chem. 14 17 (2007) 1893-1910
17. Cardus A., Parisi E., Gallego C., Aldea M., Fernandez E., and Valdivielso J.M. 1,25-Dihydroxyvitamin D3 stimulates vascular smooth muscle cell proliferation through a VEGF-mediated pathway. Kidney Int. 69 8 (2006) 1377-1384
18. Wu J., Garami M., Cheng T., and Gardner D.G. 1, 25(OH)2 vitamin D3, and retinoic acid antagonize endothelin-stimulated hypertrophy of neonatal rat cardiac myocytes. J. Clin. Invest. 97 7 (1996) 1577-1588
19. Carthy E.P., Yamashita W., Hsu A., and Ooi B.S. 1,25-Dihydroxyvitamin D3 and rat vascular smooth muscle cell growth. Hypertension 13 6 Pt 2 (1989) 954-959
20. Wu-Wong J.R., Nakane M., Ma J., Ruan X., and Kroeger P.E. Effects of Vitamin D analogs on gene expression profiling in human coronary artery smooth muscle cells. Atherosclerosis 186 1 (2006) 20-28
21. Bouillon R., Eelen G., Verlinden L., Mathieu C., Carmeliet G., and Verstuyf A. Vitamin D and cancer. J. Steroid Biochem. Mol. Biol. 102 1-5 (2006) 156-162
22. Jones P.A., Scott-Burden T., and Gevers W. Glycoprotein, elastin, and collagen secretion by rat smooth muscle cells. Proc. Natl. Acad. Sci. U.S.A. 76 1 (1979) 353-357
23. Bauer R.F., Arthur L.O., and Fine D.L. Propagation of mouse mammary tumor cell lines and production of mouse mammary tumor virus in a serum-free medium. In Vitro 12 8 (1976) 558-563
24. Chen S., and Gardner D.G. Retinoic acid uses divergent mechanisms to activate or suppress mitogenesis in rat aortic smooth muscle cells. J. Clin. Invest. 102 4 (1998) 653-662
25. Chen S., and Gardner D.G. Suppression of WEE1 and stimulation of CDC25A correlates with endothelin-dependent proliferation of rat aortic smooth muscle cells. J. Biol. Chem. 279 14 (2004) 13755-13763
26. Morey A.K., Pedram A., Razandi M., Prins B.A., Hu R.M., Biesiada E., and Levin E.R. Estrogen and progesterone inhibit vascular smooth muscle proliferation. Endocrinology 138 8 (1997) 3330-3339
27. Whelchel A., Evans J., and Posada J. Inhibition of ERK activation attenuates endothelin-stimulated airway smooth muscle cell proliferation. Am. J. Respir. Cell Mol. Biol. 16 5 (1997) 589-596
28. Morgan D.O. Principles of CDK regulation. Nature 374 6518 (1995) 131-134
29. Jensen S.S., Madsen M.W., Lukas J., Binderup L., and Bartek J. Inhibitory effects of 1alpha,25-dihydroxyvitamin D(3) on the G(1)-S phase-controlling machinery. Mol. Endocrinol. 15 8 (2001) 1370-1380
30. Scaglione-Sewell B.A., Bissonnette M., Skarosi S., Abraham C., and Brasitus T.A. A vitamin D3 analog induces a G1-phase arrest in CaCo-2 cells by inhibiting cdk2 and cdk6: roles of cyclin E, p21Waf1, and p27Kip1. Endocrinology 141 11 (2000) 3931-3939
31. Liu M., Lee M.H., Cohen M., Bommakanti M., and Freedman L.P. Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937. Genes Dev. 10 2 (1996) 142-153
32. Huang Y.C., Chen J.Y., and Hung W.C. Vitamin D3 receptor/Sp1 complex is required for the induction of p27Kip1 expression by vitamin D3. Oncogene 23 28 (2004) 4856-4861
33. Li P., Li C., Zhao X., Zhang X., Nicosia S.V., and Bai W. p27(Kip1) stabilization and G(1) arrest by 1,25-dihydroxyvitamin D(3) in ovarian cancer cells mediated through down-regulation of cyclin E/cyclin-dependent kinase 2 and Skp1-Cullin-F-box protein/Skp2 ubiquitin ligase. J. Biol. Chem. 279 24 (2004) 25260-25267
34. Segaert S., Garmyn M., Degreef H., and Bouillon R. Retinoic acid modulates the anti-proliferative effect of 1,25-dihydroxyvitamin D3 in cultured human epidermal keratinocytes. J. Invest. Dermatol. 109 1 (1997) 46-54
35. Saramaki A., Banwell C.M., Campbell M.J., and Carlberg C. Regulation of the human p21(waf1/cip1) gene promoter via multiple binding sites for p53 and the vitamin D3 receptor. Nucleic Acids Res. 34 2 (2006) 543-554
36. Verlinden L., Verstuyf A., Convents R., Marcelis S., Van Camp M., and Bouillon R. Action of 1, 25(OH)2D3 on the cell cycle genes, cyclin D1, p21 and p27 in MCF-7 cells. Mol. Cell Endocrinol. 142 1-2 (1998) 57-65
37. Boyle B.J., Zhao X.Y., Cohen P., and Feldman D. Insulin-like growth factor binding protein-3 mediates 1 alpha,25-dihydroxyvitamin d(3) growth inhibition in the LNCaP prostate cancer cell line through p21/WAF1. J. Urol. 165 4 (2001) 1319-1324
38. Weiss R.H., Joo A., and Randour C. p21(Waf1/Cip1) is an assembly factor required for platelet-derived growth factor-induced vascular smooth muscle cell proliferation. J. Biol. Chem. 275 14 (2000) 10285-10290